Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
R Polak, ET Zhang, CJ Kuo - Nature Reviews Cancer, 2024 - nature.com
The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …
malignantly transformed cells and the tumour microenvironment (TME). Cancer …
Targeted protein degradation: advances in drug discovery and clinical practice
G Zhong, X Chang, W ** spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer
The drivers of immune evasion are not entirely clear, limiting the success of cancer
immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to …
immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to …
Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus
An exome sequencing strategy employed to identify pathogenic variants in patients with
pediatric-onset systemic lupus or Evans syndrome resulted in the discovery of six novel …
pediatric-onset systemic lupus or Evans syndrome resulted in the discovery of six novel …
Inhibition of DUSP18 impairs cholesterol biosynthesis and promotes anti-tumor immunity in colorectal cancer
X Zhou, G Wang, C Tian, L Du, EV Prochownik… - Nature …, 2024 - nature.com
Tumor cells reprogram their metabolism to produce specialized metabolites that both fuel
their own growth and license tumor immune evasion. However, the relationships between …
their own growth and license tumor immune evasion. However, the relationships between …
X-CHIME enables combinatorial, inducible, lineage-specific and sequential knockout of genes in the immune system
Annotation of immunologic gene function in vivo typically requires the generation of
knockout mice, which is time consuming and low throughput. We previously developed …
knockout mice, which is time consuming and low throughput. We previously developed …
Dismantlable coronated nanoparticles for coupling the induction and perception of immunogenic cell death
H Liang, C Xu, D Guo, F Peng, N Chen… - Advanced …, 2024 - Wiley Online Library
Therapy‐induced immunogenic cell death (ICD) can initiate both innate and adaptive
immune responses for amplified anti‐tumor efficacy. However, dying cell‐released ICD …
immune responses for amplified anti‐tumor efficacy. However, dying cell‐released ICD …
PTPRT loss enhances anti–PD-1 therapy efficacy by regulation of STING pathway in non–small cell lung cancer
Z Chen, W Ji, W Feng, J Cui, Y Wang, F Li… - Science Translational …, 2024 - science.org
With the revolutionary progress of immune checkpoint inhibitors (ICIs) in non–small cell lung
cancer, identifying patients with cancer who would benefit from ICIs has become critical and …
cancer, identifying patients with cancer who would benefit from ICIs has become critical and …
Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader
L Hu, H Li, J Qin, D Yang, J Liu, X Luo… - Journal of Medicinal …, 2023 - ACS Publications
Protein tyrosine phosphatase nonreceptor Type 2 (PTPN2) is an attractive target for cancer
immunotherapy. PTPN2 and another subtype of PTP1B are highly similar in structure, but …
immunotherapy. PTPN2 and another subtype of PTP1B are highly similar in structure, but …
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy
Z Yao, Y Zeng, C Liu, H **, H Wang, Y Zhang… - Journal of Experimental …, 2024 - Springer
Vigorous CD8+ T cells play a crucial role in recognizing tumor cells and combating solid
tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain …
tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain …